BioCentury
ARTICLE | Clinical News

Gamunex immune globulin intravenous regulatory update

August 25, 2003 7:00 AM UTC

Canada approved for marketing BAYG's Gamunex 10% intravenous human immune globulin ( IGIV) to treat idiopathic thrombocytopenic purpura, primary immune deficiencies, allogeneic bone marrow transplanta...